Professional Documents
Culture Documents
Initiating Coverage
March 9, 2011
Rating Matrix
Rating Target Target Period Potential Upside : : : : Strong Buy | 257 12-15 months 34%
Stock Data
Bloomberg/Reuters Code Sensex Average volumes Market Cap (| crore) 52 week H/L Equity Capital (| crore) Promoter's Stake (%) FII Holding (%) DII Holding (%) ARBP.IN / ARBN.BO 18,439.7 149,189 5,225.6 272 / 161 29.1 54.4 26.4 9.4
Valuations
APL is currently trading at a steep discount to its industry peers due to the recent melt down and legacy issues like API model and weak balance sheet. Despite the import alert for one facility, we believe other issues like transformation from API driven model to generic formulations, incremental capacity utilisation, monetisation of the growing ANDA pipeline and recent deals with leading MNCs will remain intact. We expect the valuation gap to narrow down, going forward. We value APL at | 257, based on 9x FY13E EPS of | 28.5.
Exhibit 1: Valuation Metrics
(Year-end March) Net Sales (| crore) EBITDA (| crore) Net Profit (| crore) EPS (|) P/E (x) Price / Book (x) EV/EBITDA (x) RoCE (%) RoE (%)
Source: Company, ICICIdirect.com Research
Price movement
7,000 6,000 5,000 4,000 3,000 2,000 1,000 0 Mar-10 Jun-10 Sep-10 Dec-10
Nifty (L.H.S)
Analysts name
Siddhant Khandekar siddhant.khandekar@icicisecurities.com Krishna Kiran Konduri krishna.konduri@icicisecurities.com
FY09 3,077.3 516.4 100.2 3.4 55.7 4.5 15.1 10.9 8.1
FY10 3,575.4 823.2 563.4 19.4 9.9 3.0 9.3 16.9 30.8
FY11E 4,318.1 974.5 559.8 19.2 10.0 2.3 7.9 16.0 23.0
FY12E 4,991.9 1,149.4 641.8 22.0 8.7 2.0 6.5 19.8 23.6
FY13E 5,720.1 1,379.0 830.8 28.5 6.7 1.6 5.3 21.5 24.0
Company background
Aurobindo Pharma (APL) was set up by first generation entrepreneurs PV Ramprasad Reddy and K Nithyananda Reddy in 1986. Based in Hyderabad, APL is an integrated pharmaceutical company, which started as an API manufacturer. In 2001, it moved up the value chain by foraying into formulations while from 2007 onwards it started scaling up the formulation business. APL's manufacturing facilities are approved by several leading regulatory agencies like USFDA, UKMHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company owns 16 manufacturing facilities in India and the US. Of these 16 facilities, seven are for formulations, six are for APIs while three are for intermediates. It also owns a distribution hub in Malta and a packaging facility in Brazil. The company owns three R&D centres. The current employee strength is more than 8000, which includes more than 750 scientists. APL markets its products in 125 countries through a global marketing network of 41 subsidiaries. Till date, it has filled 200 ANDA with the USFDA and received approvals for 132 ANDAs (including 33 tentative approvals). It has also filed 906 dossiers in the EU market and received approvals for 351 dossiers. Exports account for ~70% of total sales. Aurobindo Pharma is vertically integrated and its product basket includes about 300+ products spread over seven major therapeutic areas encompassing cardiovascular (CVS), central nervous system (CNS), anti-infectives, anti-retrovirals (ARVs), gastroenterologicals (GIs), pain management and osteoporosis. The market potential of APLs product pipeline of 300+ products is more than US$200 billion. The company is a leading player in APIs and has a strong presence in anti-bacterials such as semi-synthetic penicillins (SSPs) and cephalosporins (Cephs). Explanation on Unit VI import alert USFDA has imposed an import alert on drugs manufactured at the companys Unit VI facility. Unit VI manufactures cephalosporin in both oral and sterile forms. The facility was inspected by the USFDA in December 2010 and it found some deviations in cGMP of sterile products in the facility. Currently, Aurobindo has stopped shipments to US market from this facility. Currently, Aurobindo is supplying four injections cefazolin, cefotaxime, ceftazidime and ceftriaxone from this facility to Pfizer. It is also supplying five oral products cefadroxil, cefidinir, cefprozil, cefprozil oral suspension and cefuroxime axetil to Pfizers generics unit Greenstone LLC. Annual sales to the US market from Unit VI are around US$30 million. It has filed 30 ANDAs from this facility and received approvals for 20 ANDAs so far. The company has maintained that the ANDAs filed from other manufacturing facilities will not have any impact. Pfizer has indicated that it will help Aurobindo to resolve the issue as soon as it gets clarity on the same. In all our calculations, we have considered the impact of future revenue loss from this facility.
54.4
54.4
Pfizer will work closely with Aurobindo to sort out the issue
Page 2
3301
69
61
54
46
43
31
39
46
54
57
FY10 APIs
9M FY11
Dossier Income 7%
USA 25%
APIs 40%
Page 3
Page 4
3787 3037 2412 1647 1410 1852 1602 1744 1831 1911
142
198
260
80
APIs
Page 5
54
58
62
66
Formulations
Source: Company, ICICIdirect.com Research
APLs formulation facilities have been backed by its own API facilities. The business model is vertically integrated with ~95% of the key intermediates and APIs required for formulations made in-house. This has facilitated the company to enter into other niche segments such as cardiovascular (CVS), central nervous system (CNS) and gastroenterologicals (GI), other than its traditional segments of antibacterials and ARVs. Despite that, we have also observed that the company will remain committed to anti-bacterials, especially high-end ones such as Cephalosporins (third and fourth generation) and Penems. Also, in ARVs, the company will be selective in tender selection (discussed later). Almost all formulations are meant for exports. Aurobindo has recently added two more formulations facilities (one acquired facility and one SEZ) and upgraded the New Jersey based facility. The SEZ unit VII (capex of | 270 crore), which has already gone on stream from June 2010 has the potential to clock | 1500-2000 crore of sales at the optimum level. It is expected to reach ~30% utilisation by the end of FY11. This facility will cater to the non-betalactum product class, which is also being catered to by unit III. This unit (i.e. unit III) is already working at over 85% capacity. Hence, there is a need for new capacity. The Trident facility (acquired in 2009) is expected to start commercial production in FY12. The plant is expected to manufacture the general injectable range of formulation products. The company is also building new capacities for oral contraceptives (near Unit VII) and new multipurpose non-betalactum liquid injectable facility near Hyderabad. All these acquisitions/additions will further increase formulations share. Overall, the company has invested nearly | 1000 crore in the last five years to build up the formulation capacities. Since APIs will increasingly be used for formulations, we see the share of APIs to sales coming down to ~33-34% by FY13E. The residual APIs will more or less cater to regulated markets. We project sales from APIs will grow at 6% CAGR in FY10-13E to | 1911 crore. At the same time, we expect formulations to grow at 26.9% CAGR in FY10-13E to | 3787 crore.
Unit VII has the potential to clock | 1500-2000 crore per annum
Page 6
1911
To augment large unused formulation capacity utilisation Aurobindo currently owns 16 manufacturing facilities - 15 in India and one in the US. The recently acquired Trident facility is yet to start commercial production. Overall capacity utilisation in case of most of the formulation plants is still below 50%. Over the years, the company has kept on building huge capacities. On account of the longer gestation period for formulation plants, the company did face certain balance sheet issues and cash flow constraints initially. Hence, it had to rely on borrowings, which kept on ballooning. At one point of time the debt/EBITDA stood at nearly 4.5x. However, the deal it entered into with Pfizer in 2009 was in a way a shot in the arm as the deal not only gave new strength but also provided assurances on incremental capacity utilisation. The augmented capacity utilisation will strengthen the EBIDTA margins as shown in the common-size statement.
Exhibit 13: Common-size statement
Net sales Total Exp EBITDA Depreciation Interest Tax Net Profit FY08 100 85.6 14.4 4.1 1.8 2.2 9.8 FY09 100 83.2 16.8 4.1 2.7 0.7 3.3 FY10 100 77 23.0 4.2 1.9 5.3 15.8 FY11E 100 77.4 22.6 3.8 1.4 5.5 13.0 FY12E 100 77 23.0 3.9 2.2 4.3 12.9 FY13E 100 75.9 24.1 3.7 1.8 4.8 14.5
Incremental capacity utilisation will also cater to the demand from regulated markets culminating from an impending patent cliff other than commitments to large customers like Pfizer and AstraZeneca. We believe the utilisation process will go beyond FY13 as by then the newly added facilities such as Trident for injectables, oral contraceptives and liquid injectible facilities will go on stream.
Page 7
5.4 4.5
2.6
FY08
FY09
FY10
FY11E
FY12E
FY13E
Offloaded majority stake in Chinese facility to prune losses of ~| 20-25 crore per year on a consolidated basis
It recently offloaded majority stake (from 100% to 19.5%) in its Chinese manufacturing facility that was a fermentation unit manufacturing 6 APA, a derivative of Penicillin-G. The entire production is consumed by APL India. Since the company intends to focus on high margin antibacterials, this step indicates a step by step plan to defocus on semi synthetic penicillins (SSPs) where the competition is intense and, hence, realisation is low. We observe a gradual defocus on SSPs from 23% of sales in FY09 to ~11% of sales by FY13E. Since it was a loss making unit, the company is expected to prune ~ | 20-25 crore of losses in the consolidated financials. Thanks to this offloading, the company expects to strengthen the overall cash flow and operating margins. It has also received | 104 crore as repayment of loan from the Chinese entity.
Page 8
FY09 Approved
FY10
9M FY11
We expect the US business to grow at ~27% CAGR to | 1849 crore in FY10-13E on the back of monetisation of the huge ANDA pipeline. The contribution from US to the overall sales is expected to grow from 17% in FY09 to ~32% in FY13E.
Exhibit 17: Sales from US market to grow at 27% CAGR in FY10-13E
2000 1800 1600 1400 1200 1000 800 600 400 200 0 FY08 FY09 FY10 FY11E FY12E FY13E 236 558 912 1135 1445 1849
Pfizer deal
In May 2009, APL entered into a licensing and supply agreement with Pfizer Inc. to sell over 100 products in the US, 30 countries in the EU, Canada, Australia-New Zealand and almost 110 rest of world (ROW) countries. The deal is mostly non-exclusive in nature. Supplies to Pfizer have already started in FY10. Pfizer will remain the biggest customer for the company.
AstraZeneca deal
Sales from AstraZeneca deal would start from FY13 onwards
APL recently signed a licensing and supply agreement with AstraZeneca to supply solid dosage and sterile products for emerging markets. These products will cater to therapeutic segments of anti-infectives, CVS and CNS. We expect the sales from this deal to start from FY13 onwards.
Page 9
Page 10
Similarly the ROW business, which currently forms 6% of sales, will get a boost from MNC deals, aggressive regulatory filings and growing demand for branded generics. Till date, APL has filed 233 dossiers in South Africa, Canada, Australia and Brazil. Of this, it has received approvals for 91 dossiers. Also, it has filed 415 DMFs in various countries. We expect the ROW business to grow at 32% CAGR in FY1013E to | 479 crore.
Page 11
(US$ billion)
30 20 10 0
28 20 20
28
27
2008
2009
2010
2011
2012
Page 12
The company will redeem both FCCBs in May 2011. It will require US$ 139 million for FCCB repayment and another US$65 million for YTM and withholding tax. Aurobindo will repay around US$100 million through internal accruals and roll over the remaining short fall by the FCNR (B) route. As far as unprovided premium on redemption i.e. ~| 291 crore is concerned, the company has maintained that the same will be adjusted against share premium account. We believe the companys debt position would improve significantly as incremental capacity utilisation takes place. The FCCBs form ~ 28% of the total debt. We expect the D/E ratio to come down from 1.2x in FY10 to 0.6x by FY13E.
Exhibit 23: Debt/equity to ease further
2.0 1.8 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 FY08 FY09 FY10 FY11E FY12E FY13E 1.2 1.1 0.8 0.6 1.7 1.9
Page 13
Page 14
14.4 352
FY12E
FY13E
Page 15
35.0 30.8 21.2 10.9 8.3 8.1 16.9 16.0 23.0 19.8 23.6 21.5 24.0 30.0 25.0 20.0 15.0 10.0 5.0 0.0 FY11E RONW FY12E FY13E
Page 16
(|)
Price
11.5x
18.3x
8.9x
6.2x
(| crore)
EV
14.2x
12.2x
8.3x
4.4x
(FY12E)
RoNW 23.6 25.7 18.8 17.3
Page 17
FY09 3077 26 2561 516 47 128 84 18 323 201 122 21 100 266 26 3.4 9.1
FY10 3575 16 2752 823 59 150 68 39 645 -109 754 190 563 482 81 19.4 16.5
FY11E 4318 21 3344 975 18 165 62 25 773 -26 799 239 560 542 12 19.2 18.6
FY12E 4992 16 3843 1149 18 195 110 32 876 20 856 214 642 657 21 22.0 22.6
FY13E 5720 15 4341 1379 20 211 101 40 1108 0 1108 277 831 831 26 28.5 28.5
FY09 27 1,214 1,241 988 1,345 79 3 3,656 1,855 554 1,301 536 1,837 98 0 878 128 890 387 2,289 543 27 570 1,719 2 3,656
FY10 28 1,801 1,829 864 1,291 95 4 4,083 2,263 664 1,599 570 2,169 112 0 1,102 73 956 371 2,506 673 35 708 1,798 4 4,083
FY11E 29 2,409 2,438 714 1,891 95 4 5,142 2,808 810 1,998 425 2,423 118 0 1,264 441 1,124 579 3,404 769 38 807 2,597 4 5,142
FY12E 29 2,691 2,720 814 1,291 95 4 4,924 3,208 984 2,224 350 2,574 121 0 1,198 177 1,231 619 3,229 957 48 1,005 2,224 4 4,924
FY13E 29 3,436 3,465 714 1,241 95 4 5,520 3,683 1,170 2,514 150 2,664 220 0 1,466 157 1,410 753 3,784 1,097 55 1,152 2,632 4 5,520
Page 18
FY09 100 128 -385 45 -113 -548 60 -2 6 -484 0 291 134 -28 45 0 442 -155 283 128
FY10 563 150 -272 138 579 -496 0 -2 16 -480 1 -124 -55 -32 -43 99 -154 -55 128 73
FY11E 560 165 -530 99 294 -425 0 0 0 -425 1 -150 600 -51 -30 129 499 369 73 441
FY12E 642 195 -89 198 946 -350 0 0 0 -350 0 100 -600 -68 0 -292 -860 -264 441 177
FY13E 831 211 -575 147 613 -398 0 0 0 -398 0 -100 -50 -85 0 0 -235 -20 177 157
(%)
FY13E 75.0 94.8 20.4 103.6 159.3 24.0
Page 19
FY10 19.4 16.5 24.5 62.8 28.3 23.0 21.1 15.8 30.8 16.9 12.6 FY10 9.9 11.6 9.3 2.1 1.6 3.0 2.0 3.6 3.7 5.3 2.2 1.2 3.5 3.4 2.6
FY11E 19.2 18.6 24.9 83.8 33.5 22.6 18.5 13.0 23.0 16.0 12.1 FY11E 10.0 10.3 7.9 1.8 1.3 2.3 1.8 3.7 3.8 5.6 2.2 1.1 4.2 3.7 2.7
FY12E 22.0 22.6 28.8 93.4 39.5 23.0 17.1 12.9 23.6 19.8 15.1 FY12E 8.7 8.5 6.5 1.5 1.1 2.0 1.8 4.1 4.1 5.2 2.2 0.8 3.2 3.0 1.8
3.4 9.1 7.8 42.6 17.7 16.8 4.0 3.3 8.1 10.9 9.1 FY09 55.7 21.0 15.1 2.5 1.8 4.5 2.5 3.7 3.5 5.7 2.4 1.9 4.0 3.8 4.5
FY13E (|) 28.5 28.5 35.8 119.0 47.4 (%) 24.1 19.4 14.5 (%) 24.0 21.5 16.4 FY13E (x times) 6.7 6.7 5.3 1.3 1.0 1.6 1.7 (x times) 4.3 4.1 5.2 2.3 (x times) 0.6 3.3 3.1 1.4
Page 20
ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Add, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock. Strong Buy: 20% or more; Buy: Between 10% and 20%; Add: Up to 10%; Reduce: Up to -10% Sell: -10% or more; Pankaj Pandey Head Research ICICIdirect.com Research Desk, ICICI Securities Limited, 7th Floor, Akruti Centre Point, MIDC Main Road, Marol Naka, Andheri (East) Mumbai 400 093 research@icicidirect.com ANALYST CERTIFICATION
We /I, Siddhant Khandekar CA-INTER Krishna Kiran Konduri MBA FINANCE research analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the ICICI Securities Inc.
pankaj.pandey@icicisecurities.com
Disclosures:
ICICI Securities Limited (ICICI Securities) and its affiliates are a full-service, integrated investment banking, investment management and brokerage and financing group. We along with affiliates are leading underwriter of securities and participate in virtually all securities trading markets in India. We and our affiliates have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. Our research professionals provide important input into our investment banking and other business selection processes. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their dependent family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on reasonable basis, ICICI Securities, its subsidiaries and associated companies, their directors and employees (ICICI Securities and affiliates) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities is acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return of investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities and affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. ICICI Securities and its affiliates might have managed or co-managed a public offering for the subject company in the preceding twelve months. ICICI Securities and affiliates might have received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of public offerings, corporate finance, investment banking or other advisory services in a merger or specific transaction. ICICI Securities and affiliates expect to receive compensation from the companies mentioned in the report within a period of three months following the date of publication of the research report for services in respect of public offerings, corporate finance, investment banking or other advisory services in a merger or specific transaction. It is confirmed that Siddhant Khandekar CA-INTER Krishna Kiran Konduri MBA FINANCE research analysts and the authors of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Our research professionals are paid in part based on the profitability of ICICI Securities, which include earnings from Investment Banking and other business. ICICI Securities or its subsidiaries collectively do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. It is confirmed that Siddhant Khandekar CA-INTER Krishna Kiran Konduri MBA FINANCE director or advisory board member of the companies mentioned in the report. research analysts and the authors of this report or any of their family members does not serve as an officer,
ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. ICICI Securities and affiliates may act upon or make use of information contained in the report prior to the publication thereof. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.
Page 21